OneSource Specialty Pharma Limited has informed the stock exchanges of the resignation of Prateek Gupta, Senior Vice President & Head – Technical Development, from his position as Senior Management Personnel (SMP) of the company, effective May 13, 2026. The disclosure was made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

The company filed the requisite disclosure pursuant to Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. O/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The key details of the cessation are outlined below:

Regulatory Compliance

The disclosure was submitted on behalf of OneSource Specialty Pharma Limited by Trisha A, Company Secretary and Compliance Officer (Membership Number: A47635), on May 13, 2026. As required under the applicable regulatory framework, the company confirmed that the brief profile and disclosure of relationship between directors are not applicable in this instance, given that the change pertains to a resignation rather than an appointment.

OneSource Specialty Pharma announced that its partner Orbicular, along with its Canadian front-end partner, has received approval from Health Canada for a generic version of Ozempic® (semaglutide injection). This marks the second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in what is recognized as the world's second-largest semaglutide market.

Strategic Market Milestone

The latest regulatory approval represents a significant achievement for OneSource's expanding portfolio of complex pharmaceutical partnerships in one of the world's most important semaglutide markets. The milestone reflects a closely integrated development and manufacturing model where Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner.

Manufacturing and Supply Chain Excellence

OneSource provided end-to-end manufacturing capabilities for the Canadian filing, with commercial supply to be supported from the company's US FDA-approved flagship facility in Bengaluru. The approval follows a recent tentative approval in the United States supported by OneSource, further reinforcing the company's growing presence in complex peptide-based injectable programs across highly regulated markets.

Global Market Expansion

The Canadian approval builds on momentum from India, where OneSource has been supplying multiple brands marketed by various partners following product launches in March. This strategic positioning establishes the company as a key player in the global semaglutide market across multiple jurisdictions, with particular strength in enabling first-to-market generic entries.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, commented: "We are pleased with these back-to-back approvals from two of our global customers in one of the most important semaglutide markets globally. This milestone reflects the strength of our CDMO platform, our compliance standards, technical expertise, and ability to scale complex drug-device-combination programs for highly regulated markets. Our partnership with Orbicular highlights our role in enabling global commercialization through strong, collaborative ecosystems."

CDMO Platform Capabilities

With a continued focus on complex drug-device combinations, biologics, and oral technology, OneSource is strengthening its position as a global CDMO partner. The company enables faster, reliable, and high-quality commercialization for partners worldwide through its comprehensive manufacturing and development capabilities across five state-of-the-art facilities.